<DOC>
	<DOCNO>NCT00704808</DOCNO>
	<brief_summary>The purpose surveillance collect safety efficacy data `` non-study '' patient concomitant adjuvant temozolomide therapy .</brief_summary>
	<brief_title>Post Marketing Surveillance : Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide Adjuvant Temozolomide ( Study P04739 )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must newly diagnose operate glioblastoma multiforme postoperative residual tumor &lt; =1.5 cm magnetic resonance imaging ( MRI ) . Age &gt; =18 year . Hemoglobin &gt; =10 g/dL . White blood cell count &gt; =1.5x10^9/L . Platelet count &gt; =100x10^9/L . Blood urea &lt; =1.5 x upper limit normal value ( ULN ) . Creatinine &lt; =1.5 x ULN . Bilirubin &lt; =1.5 x ULN . Aspartate aminotransferase &lt; =3 x ULN . Alanine aminotransferase &lt; =3 x ULN . Alkaline phosphatase &lt; =2 x ULN . Tumorspecific pretreatment . Contraindication radiotherapy and/or chemotherapy . Malignomas basaliomas . Existing planned pregnancy lactation inadequate contraception . Psychiatric disease . Simultaneous participation another clinical trail participation another clinical trail last 30 day recruitment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>